Highlights Venus Remedies Limited NSE India S.E.

Equities

VENUSREM

INE411B01019

Delayed NSE India S.E. Other stock markets 10:41:46 14/05/2024 am IST			5-day change	1st Jan Change
308.5 ^INR	+4.68%		-0.63%	-24.06%

19/03	Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	MT
08/03	Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Venus Remedies Secures Marketing Authorizations in Ukraine for Three Oncology Drugs	19/03	MT
Venus Remedies Gets Ukraine's Marketing Approval for Three Oncology Products	08/03	MT
Venus Remedies Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Venus Remedies Gets Ukraine Marketing Approval for Chemotherapy Drug, Antibiotics	13/02	MT
Venus Remedies Gets Marketing Authorization in Malta for Two Chemotherapy Drugs	12/01	MT
Venus Remedies Gets Authorization to Market Cancer Drugs in Israel, Colombia	21/12	MT
Venus Remedies Expands Into Wellness Business	20/12	MT
Venus Remedies Gets Bahrain Marketing Authorization for Enoxaparin	19/12	MT
Venus Remedies Gets Azerbaijan's Marketing Approval for Blood Clot Prevention Drug	05/12	MT
Venus Remedies Gets Marketing Approval for Cancer Drugs in Philippines, Saudi Arabia	01/12	MT
Venus Remedies Limited Receives Market Authorizations in Saudi Arabia and Philippines	01/12	CI
Venus Remedies' Consolidated Profit Jumps in Fiscal Q2	27/11	MT
Venus Remedies Arm Gets Authorization to Market Cancer Drug in UK	26/23/26	MT
Venus Remedies Secures Marketing Approval for Six Key Chemotherapy Drugs in Philippines	16/23/16	MT
Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs	16/23/16	CI
Venus Remedies Launches Antibiotic Elores in Ecuador	12/23/12	MT
Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador	12/23/12	CI
Venus Remedies Gets Marketing Authorization from Serbia for Chemotherapy Drugs	20/23/20	MT
Venus Remedies Limited Extends Its Oncology Portfolio in South Eastern Europe with Serbian Marketing Approval for Gemcitabine and Docetaxel	20/23/20	CI
Venus Remedies Gets Saudi Arabia Marketing Approval for Enoxaparin	28/23/28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Venus Remedies Limited NSE India S.E.

Equities

VENUSREM

INE411B01019

Highlights

Filters